MedTrace Logo

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

NCT00860067 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1800

Last updated 2011-12-05

Study results available
· View outcomes & findings →

Summary

The objective of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV; MEDI3250) produced antibody levels similar to those produced by the commercial vaccine, FluMist.

Conditions

  • Healthy or Stable Underlying Chronic Medical Condition

Interventions

BIOLOGICAL

Q/LAIV (MEDI3250)

0.2 mL dose at Day 0

BIOLOGICAL

FluMist/B/Yamagata

0.2 mL dose at Day 0

BIOLOGICAL

FluMist/B/Victoria

0.2 mL dose at Day 0

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Judith Falloon, M.D. · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-05-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860067 on ClinicalTrials.gov